Intellia Therapeutics, Inc.

Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 86.2% of Bicycle

Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event.

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) shares passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $12.10 and traded as low as $11.37. Intellia Therapeutics shares last traded at $11.49, with a volume of 4,586,846 shares traded. Analyst Upgrades and Downgrades